CANCER PATIENTS

Tulane has joined other institutions across the globe in a trial of a drug, TL-895, to treat severe COVID-19 in hospitalized cancer patients. Dr. Nakhle Saba, associate professor of clinical medicine at the School of Medicine, is principal investigator of the trial. Saba said that data show 40% of COVID-19 patients with cancer required hospitalization, 20% developed severe respiratory illness, and 12% died within 30 days.

Horizontal thumbnail